These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

150 related items for PubMed ID: 35483215

  • 1. Sustained inhibition of ENaC in CF: Potential RNA-based therapies for mutation-agnostic treatment.
    Kota P.
    Curr Opin Pharmacol; 2022 Jun; 64():102209. PubMed ID: 35483215
    [Abstract] [Full Text] [Related]

  • 2. Targeting ENaC as a Molecular Suspect in Cystic Fibrosis.
    Bangel-Ruland N, Tomczak K, Weber WM.
    Curr Drug Targets; 2015 Jun; 16(9):951-7. PubMed ID: 25544019
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Ursodeoxycholic acid inhibits ENaC and Na/K pump activity to restore airway surface liquid height in cystic fibrosis bronchial epithelial cells.
    Mroz MS, Harvey BJ.
    Steroids; 2019 Nov; 151():108461. PubMed ID: 31344409
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. New generation ENaC inhibitors detach cystic fibrosis airway mucus bundles via sodium/hydrogen exchanger inhibition.
    Giorgetti M, Klymiuk N, Bähr A, Hemmerling M, Jinton L, Tarran R, Malmgren A, Åstrand A, Hansson GC, Ermund A.
    Eur J Pharmacol; 2021 Aug 05; 904():174123. PubMed ID: 33974881
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Low temperature and chemical rescue affect molecular proximity of DeltaF508-cystic fibrosis transmembrane conductance regulator (CFTR) and epithelial sodium channel (ENaC).
    Qadri YJ, Cormet-Boyaka E, Rooj AK, Lee W, Parpura V, Fuller CM, Berdiev BK.
    J Biol Chem; 2012 May 11; 287(20):16781-90. PubMed ID: 22442149
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Regulation of endogenous ENaC functional expression by CFTR and ΔF508-CFTR in airway epithelial cells.
    Rubenstein RC, Lockwood SR, Lide E, Bauer R, Suaud L, Grumbach Y.
    Am J Physiol Lung Cell Mol Physiol; 2011 Jan 11; 300(1):L88-L101. PubMed ID: 20935229
    [Abstract] [Full Text] [Related]

  • 16. ENaC inhibitors for the treatment of cystic fibrosis.
    Butler R, Hunt T, Smith NJ.
    Pharm Pat Anal; 2015 Jan 11; 4(1):17-27. PubMed ID: 25565157
    [Abstract] [Full Text] [Related]

  • 17. Effects of the serine/threonine kinase SGK1 on the epithelial Na(+) channel (ENaC) and CFTR: implications for cystic fibrosis.
    Wagner CA, Ott M, Klingel K, Beck S, Melzig J, Friedrich B, Wild KN, Bröer S, Moschen I, Albers A, Waldegger S, Tümmler B, Egan ME, Geibel JP, Kandolf R, Lang F.
    Cell Physiol Biochem; 2001 Jan 11; 11(4):209-18. PubMed ID: 11509829
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Epithelial sodium channel inhibition in primary human bronchial epithelia by transfected siRNA.
    Caci E, Melani R, Pedemonte N, Yueksekdag G, Ravazzolo R, Rosenecker J, Galietta LJ, Zegarra-Moran O.
    Am J Respir Cell Mol Biol; 2009 Feb 11; 40(2):211-6. PubMed ID: 18723440
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.